N/A N=53 Chlorhexidine Dressings for Hemodialysis Catheter Exit Site Care: Comparative Study
Hemodialysis Catheter Infection
Primary: Bacteraemia Rate — 2; 1 episodes — p=1.00
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=806 Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection
Kidney Failure, Chronic · Catheter-Related Infections
Primary: Presence of a CAC-Adjudicated Catheter-Related Bloodstream Infection (CRBSI) in Subjects Receiving Hemodialysis for the Treatment of End Stage Renal Disease (ESRD)…
N/A N=599 Dialysis Catheter Comparative Clinical Trial
End Stage Renal Disease
Primary: First Catheter Induced Complication — 78; 77 percentage of participants
Phase 4 N=303 Prophylactic Antimicrobial Catheter Lock
Bacteremia
Primary: Rate of Device-related Bacteremia — 30; 11 Number of infections
N/A N=149 Hub Cleansing to Prevent Hub Infection
Bacteremia
Primary: Number of Central Venous Catheter Hubs With Internal Contamination — 42; 18; 39; 14 contaminated hubs
N/A N=26 Catheter System Feasibility Clinical Trial
Renal Insufficiency, Chronic
Primary: Number of Participants With Sufficient Patency for Clinical Access — 20 Participants
N/A N=80 Comparison of Tesio and LifeCath Twin Permanent Dialysis Catheters
Hemodialysis
Primary: Blood Flow Rate at First Use After Insertion — 277; 383 mL/min
N/A N=105 DIVINE: Dialysis Infection and Vitamin D In New England
End Stage Renal Disease
Primary: Serum 25D Level — 49.8; 38.3; 27.3 ng/ml
N/A N=164 Arteriovenous Fistula Cannulation Practices and Dialysis Adequacy
Arteriovenous Fistula · Hemodialysis · Dialysis Adequacy
Primary: Number of Fistula Needle Direction — 72; 92 Participants
N/A N=33 HeRO Graft Compared to Permanent Catheters for End Stage Renal Disease (ESRD) Patients Receiving Hemodialysis
End Stage Renal Disease (ESRD)
Primary: Mortality — 18.8; 29.4 percentage of participants who died — p=0.48
Phase 3 N=223 A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters
Dysfunctional Hemodialysis Catheters
Primary: Percentage of Participants Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1 — 34.1 Percentage of participants
Phase 3 N=150 A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis Catheters
Dysfunctional Hemodialysis Catheters
Primary: Percentage of Subjects Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1 — 21.6; 5.3 percentage of success — p=0.0044
Phase 4 N=8 Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis
Acute Kidney Failure
Primary: Ertapenem Transmembrane Clearance by Continuous Hemodialysis. — 10.4 mL/min
N/A N=64 Treatment of Peritonitis in Automated Peritoneal Dialysis
Secondary Peritonitis
Primary: Peritonitis Resolved — 26; 29 participants — p=<0.05
Phase 4 N=17 Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients
Arteriovenous Fistula
Primary: Clotting TIme — 6; 8 minutes
Phase 2 N=99 Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion
Urinary Tract Infections · Catheter Infection · Catheter-Related Infections
Primary: Number of Participants With a Catheter Associated Urinary Tract Infection (CAUTI) — 7; 6 Participants
Phase 2 N=41 Catheter Related - Gram Positive Bloodstream Infections
Bloodstream Infection
Primary: Clinical Response Within 48 Hours — 28 Participants
N/A N=72 Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study
Renal Failure Chronic Requiring Hemodialysis
Primary: Percentage of Patients With Primary Patency — 48.2; 47.0; 30.6; 34.8 percentage of participants patent
N/A N=165 Passive Disinfection Cap Compliance Study
Infection, Hospital
Primary: Disinfecting Barrier Cap Compliance — 98.43 percentage of connector with compliance
N/A N=100 VectorFlow Tunneled Dialysis Catheter (TDC) Versus Palindrome TDC
Renal Failure Chronic Requiring Hemodialysis · Chronic Renal Insufficiency
Primary: Primary Patency - Intervention-free Interval (Measured in Weeks) — 89.1; 95.5; 79.4; 87.2 percentage of primary patency
N/A N=1,229 Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap
End Stage Renal Disease (ESRD)
Primary: Positive Blood Cultures (PBCs) Per 1,000 Central Venous Catheter (CVC)-Days — 0.26; 0.59 PBCs per 1,000 CVC-days
N/A N=14 Buttonhole Versus Step Ladder Cannulation in High Dose Hemodialysis
Renal Failure
Primary: Feasibility of Participant Recruitment and Site Coordination — 8; 6 Participants
N/A N=103 Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD
End Stage Renal Disease · AV Fistula · Fistula
Primary: Maturation Success Rate at 90 Days — 92 Participants
Phase 2 N=20 t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection
Central Venous Catheter Thrombosis · Central Venous Catheter Associated Bloodstream Infection
Primary: Catheter-associated Venous Thrombosis — 3; 3 Participants
Phase 2 N=6 8.4% Sodium Bicarbonate Locks in Intestinal Failure
Intestinal Failure · CRBSI - Catheter Related Bloodstream Infection
Primary: Rate of Catheter Related Bloodstream Infections — 8.2; 3.0 infections per 1000 catheter days
N/A N=338 A Prospective Study of Airless Tubing in an Inpatient Acute Hemodialysis Unit in Hospitalized Patients
End Stage Renal Failure on Dialysis · Complication of Dialysis · Blood Coagulation Disorders
Primary: Clotting of Extracorporeal Dialysis Circuit — 30; 33 Clotting events — p=0.79
N/A N=6 Intradialytic Drug Removal by Short-daily Hemodialysis
End Stage Renal Disease · Infection
Primary: Intradialytic Clearance of Levofloxacin, Gentamicin and Vancomycin in Patients Receiving Short-daily Hemodialysis — 7.2; 7.6 ml/min
N/A N=8 Continuous Cardiac Arrhythmia Monitoring in Hemodialysis Patients
Arrhythmias, Cardiac
Primary: Number of Participants With a Significant Arrhythmia Detected — 0 participants
Phase 4 N=8 Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD)
Critically Ill · Hemodialysis
Primary: Daptomycin Transmembrane Clearance by Continuous Venovenous Hemodialysis — 6.3 mL/min
N/A N=15 Safety Evaluation of Seraph® 100 to Reduce Bacteremia in Patients on Hemodialysis
Bacteremia · Bacterial Infection
Primary: Demonstrate Safety of the ExThera Medical Seraph® 100 Microbind® Affinity Blood Filter in a Hemodialysis Circuit Assessed by Rate of Adverse Events. — 0 Percent…